Elevated serum triglycerides with clozapine resolved with risperidone in four patients

Area of Science:

• Psychiatry
• Pharmacology
• Metabolic Disorders

Background:

• Clozapine and risperidone are atypical antipsychotics used to treat psychotic disorders.
• Atypical antipsychotics are associated with metabolic side effects, including dyslipidemia.
• Previous research suggests clozapine may elevate serum triglyceride levels.

Observation:

• Four patients with psychotic disorders experienced decreased serum triglyceride levels after switching from clozapine to risperidone.
• In two patients, reinstituting clozapine after discontinuing risperidone led to increased serum triglyceride levels.

Findings:

• The observed changes in serum triglyceride levels upon switching between clozapine and risperidone are consistent with clozapine's potential to elevate these levels.
• Elevated serum triglycerides have also been reported with other atypical antipsychotics like olanzapine and quetiapine.

Implications:

• Serum triglyceride levels should be closely monitored in patients with psychotic disorders receiving clozapine, especially those with existing cardiac risk factors.
• These findings highlight the importance of pharmacovigilance for metabolic side effects of antipsychotic medications.
• Further research is warranted to elucidate the mechanisms underlying clozapine-induced hypertriglyceridemia.